MX371139B - Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada. - Google Patents

Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.

Info

Publication number
MX371139B
MX371139B MX2016012846A MX2016012846A MX371139B MX 371139 B MX371139 B MX 371139B MX 2016012846 A MX2016012846 A MX 2016012846A MX 2016012846 A MX2016012846 A MX 2016012846A MX 371139 B MX371139 B MX 371139B
Authority
MX
Mexico
Prior art keywords
preparation
controlled release
release characteristics
plga microspheres
peptide loaded
Prior art date
Application number
MX2016012846A
Other languages
English (en)
Spanish (es)
Other versions
MX2016012846A (es
Inventor
Karavas Evangelos
Koutris Efthymios
Minioti Katerina
CHAITIDOU Sotiria
Papanikolaou Georgia
Mantourlias Theofanis
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Publication of MX2016012846A publication Critical patent/MX2016012846A/es
Publication of MX371139B publication Critical patent/MX371139B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2016012846A 2014-03-31 2014-03-31 Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada. MX371139B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/000858 WO2015149820A1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics

Publications (2)

Publication Number Publication Date
MX2016012846A MX2016012846A (es) 2017-05-09
MX371139B true MX371139B (es) 2020-01-20

Family

ID=50486884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012846A MX371139B (es) 2014-03-31 2014-03-31 Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.

Country Status (22)

Country Link
US (1) US9943483B2 (US07935481-20110503-C00024.png)
EP (1) EP3125871B1 (US07935481-20110503-C00024.png)
JP (1) JP6494657B2 (US07935481-20110503-C00024.png)
KR (1) KR102218655B1 (US07935481-20110503-C00024.png)
CN (2) CN114191538A (US07935481-20110503-C00024.png)
AU (1) AU2014389015B2 (US07935481-20110503-C00024.png)
BR (1) BR112016022550B1 (US07935481-20110503-C00024.png)
CA (1) CA2944561C (US07935481-20110503-C00024.png)
CY (1) CY1124037T1 (US07935481-20110503-C00024.png)
DK (1) DK3125871T3 (US07935481-20110503-C00024.png)
EA (1) EA032580B1 (US07935481-20110503-C00024.png)
ES (1) ES2837044T3 (US07935481-20110503-C00024.png)
HR (1) HRP20210058T1 (US07935481-20110503-C00024.png)
HU (1) HUE052289T2 (US07935481-20110503-C00024.png)
LT (1) LT3125871T (US07935481-20110503-C00024.png)
MX (1) MX371139B (US07935481-20110503-C00024.png)
PL (1) PL3125871T3 (US07935481-20110503-C00024.png)
PT (1) PT3125871T (US07935481-20110503-C00024.png)
RS (1) RS61209B1 (US07935481-20110503-C00024.png)
SI (1) SI3125871T1 (US07935481-20110503-C00024.png)
WO (1) WO2015149820A1 (US07935481-20110503-C00024.png)
ZA (1) ZA201607413B (US07935481-20110503-C00024.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089160A1 (en) 2012-12-04 2014-06-12 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
WO2016070117A1 (en) 2014-11-02 2016-05-06 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
KR102068578B1 (ko) * 2016-08-16 2020-01-21 중앙대학교 산학협력단 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법
CN110139826A (zh) * 2016-12-12 2019-08-16 法斯瑞斯公司 具有负的表面电荷的微粒和纳米颗粒
CN108113975B (zh) * 2018-02-02 2020-10-09 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CN109106688B (zh) * 2018-08-22 2021-08-17 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
JP6810502B1 (ja) * 2020-05-08 2021-01-06 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
JP6792900B1 (ja) * 2020-05-08 2020-12-02 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
CN116327735A (zh) * 2020-05-08 2023-06-27 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116139256A (zh) * 2023-03-14 2023-05-23 复旦大学附属肿瘤医院 生长抑素/生长抑素类似物缓释膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels

Also Published As

Publication number Publication date
PL3125871T3 (pl) 2021-04-19
EA032580B1 (ru) 2019-06-28
AU2014389015B2 (en) 2019-05-09
DK3125871T3 (da) 2020-12-21
CN114191538A (zh) 2022-03-18
ZA201607413B (en) 2018-11-28
CA2944561C (en) 2019-06-18
EP3125871B1 (en) 2020-10-21
MX2016012846A (es) 2017-05-09
SI3125871T1 (sl) 2021-03-31
EA201691884A1 (ru) 2017-02-28
EP3125871A1 (en) 2017-02-08
KR102218655B1 (ko) 2021-02-22
HUE052289T2 (hu) 2021-04-28
RS61209B1 (sr) 2021-01-29
LT3125871T (lt) 2020-12-28
KR20160137608A (ko) 2016-11-30
BR112016022550A2 (US07935481-20110503-C00024.png) 2017-08-15
CY1124037T1 (el) 2022-03-24
US9943483B2 (en) 2018-04-17
ES2837044T3 (es) 2021-06-29
CN106170284A (zh) 2016-11-30
BR112016022550B1 (pt) 2023-03-28
JP2017509661A (ja) 2017-04-06
US20170281547A1 (en) 2017-10-05
HRP20210058T1 (hr) 2021-03-05
JP6494657B2 (ja) 2019-04-03
AU2014389015A1 (en) 2016-09-29
WO2015149820A1 (en) 2015-10-08
CA2944561A1 (en) 2015-10-08
PT3125871T (pt) 2021-01-06

Similar Documents

Publication Publication Date Title
MX371139B (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
MX2021000174A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
EP3280541A4 (en) SWITCHABLE NUMERIC GENERATION AND RELEASE OF PERFUMES, AND METHODS AND SYSTEMS FOR DISPENSING STEAM AND LIQUID
IL254813A0 (en) Sustained-release injectable formulations containing isoxazoline active agent and methods and uses thereof
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
PH12016501841A1 (en) Immunosuppressant formulation
PH12016501825B1 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2017014235A (es) Formulaciones de emulsion estable de compuestos volatiles encapsulados.
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
EP3448360A4 (en) BIODEGRADABLE MICROSPHERIC COMPOSITIONS FOR PARENTERAL ADMINISTRATION
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EP3373977A4 (en) CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
EP3368609A4 (en) MULTIFUNCTIONAL BIODEGRADABLE CARRIER FOR ACTIVE INJECTION
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
IN2014MU00781A (US07935481-20110503-C00024.png)
成辉 et al. HAPPY VALENTINE’S DAY
胡淑君 Jokes and Humor
李占山 Predicting Hematology Toxicity and Choosing Starting Dose of Paclitaxel: Comparison of 3 kinds of Infusion Schedules
任存金 et al. Make Snowmen

Legal Events

Date Code Title Description
FG Grant or registration